Alyeska Investment Group
EVFM

Alyeska Investment Group’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Alyeska Investment Group’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,667
Closed -$175K – 1008
2021
Q1 		$175K Buy
+6,667
New +$303K ﹤0.01% 706
2020
Q3 		– Sell
-6,667
Closed -$283K – 629
2020
Q2 		$283K Hold
6,667
– – ﹤0.01% 454
2020
Q1 		$532K Hold
6,667
– – 0.01% 329
2019
Q4 		$617K Hold
6,667
– – 0.01% 346
2019
Q3 		$504K Hold
6,667
– – 0.01% 358
2019
Q2 		$664K Hold
6,667
– – 0.01% 392
2019
Q1 		$350K Hold
6,667
– – ﹤0.01% 355
2018
Q4 		$419K Hold
6,667
– – 0.01% 336
2018
Q3 		$405K Hold
6,667
– – ﹤0.01% 383
2018
Q2 		$271K Buy
+6,667
New +$524K ﹤0.01% 436

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Alyeska Investment Group's EVFM Position: Q3 2022 in Review

Alyeska Investment Group sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 1,950,607 shares — an estimated $2.2M sold.

Alyeska Investment Group first reported a position in EVFM in Q4 2014 and held it in 7 quarters. The position peaked at $2.2M in Q2 2022. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • Alyeska Investment Group reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Alyeska Investment Group sold 1,950,607 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $2.2M.
  • Alyeska Investment Group first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2014 and held it in 7 quarters.
  • Alyeska Investment Group's Evofem Biosciences, Inc. Common Stock position peaked at $2.2M in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on Alyeska Investment Group's 13F filing for Q3 2022, filed 14 Nov 2022.